Johnson & Johnson (NYSE:JNJ) recently presented promising data on TREMFYA® for ulcerative colitis and Crohn's disease, ...

Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis: San Diego, California Tuesday, May 6, 2 ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...

Johnson & Johnson (J&J) has announced that its dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the ...

Please provide your email address to receive an email when new articles are posted on . Tremfya is an interleukin-23 inhibitor being evaluated for the treatment of psoriatic arthritis. Twenty-four ...

Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. Find out why I remain ...

Drug major Johnson & Johnson (JNJ) announced Monday positive new data from the Phase 3 ASTRO study evaluating TREMFYA (guselkumab) subcutaneous (SC) induction therapy ...

The "Hidradenitis Suppurativa Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's ...